Alison Brand
Overview
Explore the profile of Alison Brand including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
831
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee Y, Whitely A, Burling M, Anderson L, Cohen P, Naidoo M, et al.
Int J Gynecol Cancer
. 2025 Feb;
35(2):100052.
PMID: 39971437
Objective: The Rare Ovarian Tumor Module forms part of the National Gynae-Oncology Registry (NGOR) which measures compliance with the optimal care pathways for gynecologic cancer in Australia. Our objectives were...
2.
Dimitrova D, Boer J, Karaman M, Bookman M, Brand A, ODonnell J, et al.
Int J Gynecol Cancer
. 2025 Feb;
35(2):101625.
PMID: 39971426
Objective: Clinical trials require the inclusion of all relevant demographic groups, including under-represented populations, to ensure accurate and representative findings. The aim of the study was to assess the status...
3.
Obermair A, Gebski V, Goh J, Kuchel A, Brand A, Mak B, et al.
Int J Gynecol Cancer
. 2025 Feb;
:101644.
PMID: 39955187
Background: The standard treatment for endometrial cancer is hysterectomy with or without bilateral salpingo-oophorectomy; however, this may not be an optimal choice for women who have not completed childbearing or...
4.
Derin X, Bilir E, Nasser S, Elghanmi A, Brand A, Nout R, et al.
Int J Gynecol Cancer
. 2025 Feb;
:101632.
PMID: 39955178
No abstract available.
5.
Maki P, Rubin L, Krejany E, Brand A, Hickey M
Gynecol Oncol
. 2025 Jan;
193:141-147.
PMID: 39879693
Objective: Women with BRCA1/2 pathogenic variants considering risk-reducing bilateral oophorectomy (RRSO) may be concerned about potential effects of surgical menopause on cognition. Whether RRSO affects cognition and whether hormone therapy...
6.
Obermair H, Elhindi J, Brand A, Herbst U
Gynecol Oncol Rep
. 2024 Dec;
56:101544.
PMID: 39624202
Vulvar squamous cell carcinomas (SCC) represent a heterogeneous group of patients with implications for prognosis and response to treatment. Human papillomavirus (HPV)-associated SCC is characterised by p16 positivity, whereas non-HPV...
7.
Hickey M, Nguyen T, Krejany E, Domchek S, Brand A, Hopper J, et al.
Gynecol Oncol
. 2024 Nov;
192():1-7.
PMID: 39504590
Objective: For women with pathogenic variants in BRCA1 and BRCA2, risk-reducing salpingo-oophorectomy (RRSO) at the recommended age causes surgical menopause. We previously reported elevated depressive symptoms at 6 and 12 ...
8.
Hickey M, Trainer A, Krejany E, Brand A, Domchek S, Soo V, et al.
Gynecol Oncol
. 2024 Oct;
191:201-211.
PMID: 39442373
Objective: To measure vasomotor symptoms and menopause-related quality of life up to 24 months after RRSO, and the effects of Menopausal Hormone Therapy (MHT). Methods: Prospective observational study of 104...
9.
Creutzberg C, Kim J, Eminowicz G, Allanson E, Eberst L, Kim S, et al.
Lancet Oncol
. 2024 Aug;
25(9):e420-e431.
PMID: 39214113
The Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Consensus Conference on Clinical Research (ECCC) was held in Incheon, South Korea, Nov 2-3, 2023. The aims were to develop consensus statements for...
10.
Subramanian H, Trivedi R, Fuchsova V, Elder E, Brand A, Howle J, et al.
Sleep Breath
. 2023 Dec;
28(2):725-733.
PMID: 38051468
Purpose: To assess changes in sleep-related symptoms in patients with breast cancer, endometrial cancer and melanoma previously examined for sleep-related symptoms and the presence of PSG (polysomnography)-determined OSA, ≥ 3 ...